Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month Low - What's Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $28.50 and last traded at $28.56, with a volume of 41338 shares traded. The stock had previously closed at $29.11.

Analyst Ratings Changes

COLL has been the subject of a number of research reports. HC Wainwright lifted their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, September 5th. Piper Sandler reissued a "neutral" rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $42.60.

Collegium Pharmaceutical Trading Down 1.7 %

The company has a market capitalization of $922.67 million, a P/E ratio of 12.33 and a beta of 0.80. The business has a 50 day moving average price of $31.38 and a 200 day moving average price of $34.18. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after buying an additional 792 shares during the period. CWM LLC increased its holdings in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after acquiring an additional 736 shares in the last quarter. nVerses Capital LLC increased its holdings in shares of Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 1,600 shares in the last quarter. TD Private Client Wealth LLC raised its position in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after purchasing an additional 483 shares during the period. Finally, Virtus Fund Advisers LLC bought a new position in shares of Collegium Pharmaceutical during the 3rd quarter valued at about $72,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.